Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of everolimus and exemestane in treatment of advanced breast cancer.

Trial Profile

Efficacy and safety of everolimus and exemestane in treatment of advanced breast cancer.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms BRAWO
  • Most Recent Events

    • 06 Jun 2017 Updated results of 3rd interim analysis, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results (data cut-off 18 Oct 2016; n=1345) of third interim analysis, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 12 Dec 2015 3rd Interim results (n=1300) presented at the 38th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top